Rotterdam, Netherlands
Rotterdam, Netherlands

Erasmus University Rotterdam is a renowned public university located in Rotterdam, the Netherlands, in the city that also houses the largest port in Europe. The university is named after Desiderius Erasmus Roterodamus, a 15th-century humanist and theologian. Erasmus for centuries has enjoyed popularity in academia, being a person who should always be remembered by Rotterdam.Erasmus University Rotterdam has been among the best in all kinds of world rankings. In 2007, Erasmus University Rotterdam ranked top ten of the top universities in Europe by " Financial Times ". In 2014, Erasmus University Rotterdam is ranked by Times Higher Education as 20th in Europe and 73rd in the world, with its social science as 47th, and clinical and health as 37th in the world.The university has seven faculties and focuses on four areas of expertise.Health - Faculty of Medicine and Health science/Erasmus MC and institute of Health Policy & Management Wealth - Erasmus School of Economics and Rotterdam School of Management, Erasmus UniversityGovernance - Erasmus School of Law and Faculty of Social scienceCulture - Erasmus School of History, Culture and Communication, Faculty of Social science and Faculty of PhilosophyErasmus MC is the largest and one of the foremost academic medical centers and trauma centers in the Netherlands, whereas its economics and business school, Erasmus School of Economics and Rotterdam School of Management, Erasmus University are leading economics school and business school within Europe and the world. Wikipedia.


Time filter

Source Type

Patent
Erasmus University Rotterdam and Skylinedx B.V. | Date: 2015-03-28

The disclosure is in the field of medical treatments and relates to the treatment of cancer, in particular, multiple myeloma (MM). Even more in particular, it provides means and methods for the improved treatment of certain subgroups of MM patients, more in particular, subjects with a poor prognosis. In a particular embodiment, the disclosure provides a method of treatment wherein subjects with a poor prognosis are selected and treated with a proteasome inhibitor such as Bortezomib. The disclosure further provides means and methods for identifying subjects with a poor prognosis. More in particular, the disclosure provides a composition comprising a proteasome inhibitor for use in the treatment of a subject with multiple myeloma when the subject has been diagnosed with an amp1q chromosomal aberration.


Patent
Erasmus University Rotterdam | Date: 2017-04-19

The disclosure provides method and kits for characterizing spliced m RNA isoforms. The disclosure also provides methods of screening for mutations and oligonucleotides that modulate splicing.


The invention relates to the field of cancer diagnosis and therapy design, in particular diagnosis of extramedullary (EM) involvement in a subject afflicted with acute lymphoblastic leukemia. Provided is a method comprising determining in ALL cells the relative level and/or absolute amount of Stearoyl-Co A desaturase (SCD; EC 1.14.19.1) protein; and correlating the level and/or absolute amount of the SCD protein with the risk of developing an EM relapse, wherein an increased level and/or absolute amount of SCD relative to a control sample is indicative of having an increased risk of developing an extramedullary relapse. Also provided are reagent compositions and a diagnostic kit.


Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. Also provided are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular, provided is a mammalian MPV, subgroups and variants thereof. Also provided are genomic nucleotide sequences of different isolates of mammalian MPV, in particular, human MPV. Disclosed is the use of the sequence information of different isolates of mammalian MPV for diagnostic and therapeutic methods. Provided are nucleotide sequences encoding the genome of an MPV or a portion thereof, including both mammalian and avian MPV. Further described are chimeric or recombinant viruses encoded by the nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences. Also provided are vaccine formulations comprising mammalian or avian MPV, including recombinant and chimeric forms thereof. The vaccine preparations encompass multivalent vaccines, including bivalent and trivalent vaccine preparations.


Patent
Erasmus University Rotterdam | Date: 2017-04-19

The present invention is directed to antisense oligomeric compounds that may be used in the treatment Pompe disease as well as method for modulating the splicing of the GAA gene and method to treat Pompe disease. Also pharmaceutical compositions comprising the antisense oligomeric compounds are part of the invention.


Patent
Erasmus University Rotterdam and Skylinedx B.V. | Date: 2017-02-01

The invention is in the field of medical treatments and relates to the treatment of cancer, in particular multiple myeloma (MM). Even more in particular it provides means and methods for the improved treatment of certain subgroups of MM patients, more in particular subjects with a poor prognosis. In a particular embodiment, the invention provides a method of treatment wherein subjects with a poor prognosis are selected and treated with a proteasome inhibitor such as Bortezomib. The invention further provides means and methods for identifying subjects with a poor prognosis. More in particular, the invention provides a composition comprising a proteasome inhibitor for use in the treatment of a subject with multiple myeloma wherein the subject has been diagnosed with an amp1q chromosomal aberration.


Patent
Erasmus University Rotterdam | Date: 2014-05-20

The disclosure is in the field of medical treatments and relates to the treatment of multiple myeloma (MM). In particular, it provides means and methods for the improved treatment of certain subgroups of MM patients, more in particular, patients with a poor prognosis. In a particular embodiment, the disclosure provides a method for determining whether a subject with multiple myeloma is likely to respond to a treatment with a proteasome inhibitor wherein the method comprises the step of performing, on a sample from the subject, a gene expression analysis of a number of N genes selected from the group consisting of the genes NUAK1, ITGB7, AGMAT, TFAP2C, CCDC85A, CLEC7A, TMEM37, RNF144A, and CMPK2, wherein N is at least 2 and wherein it is concluded that the subject is likely to respond to a treatment with a proteasome inhibitor in the case where at least two of the N genes are aberrantly expressed.


Patent
Erasmus University Rotterdam | Date: 2017-03-08

The invention relates to the field of virology. The invention provides an isolated essentially mammalian negative-sense single-stranded RNA virus (MPV) within the subfamily Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus and components thereof.


Patent
Erasmus University Rotterdam | Date: 2017-03-29

The invention is in the field of medical treatments and relates to the treatment of multiple myeloma (MM). In particular it provides means and methods for the improved treatment of certain subgroups of MM patients, more in particular patients with a poor prognosis. In a particular embodiment, the invention provides a method for determining whether a subject with multiple myeloma is likely to respond to a treatment with a proteasome inhibitor wherein the method comprises the step of performing, on a sample from the subject, a gene expression analysis of a number of N genes selected from the group consisting of the genes NUAK1, ITGB7, AGMAT, TFAP2C, CCDC85A, CLEC7A, TMEM37, RNF144A, and CMPK2, wherein N is at least 2and wherein it is concluded that the subject is likely to respond to a treatment with a proteasome inhibitor in case that at least 2 of said N genes are aberrantly expressed.


Zwaan R.A.,Erasmus University Rotterdam
Trends in Cognitive Sciences | Year: 2014

The debate on whether language comprehension involves the manipulation of abstract symbols or is grounded in perception and action has reached an impasse, with authors from different theoretical persuasions unable to agree on the diagnostic value of empirical findings. To escape this impasse, I propose a pluralist view of cognition that encompasses abstract and grounded symbols. The contributions of these symbol types to language comprehension vary as a function of the degree to which language use is embedded in the environment. I distinguish five levels of embeddedness: demonstration, instruction, projection, displacement, and abstraction. Only through a closer analysis of context will we make significant progress toward understanding language comprehension and cognition in general. © 2014 Elsevier Ltd.

Loading Erasmus University Rotterdam collaborators
Loading Erasmus University Rotterdam collaborators